[ad_1]
The National Institute for Health and Care Excellence (NIHR), Innovation UK, the Advanced Therapeutics Center Network and the Cell and Gene Therapy Catapult (CGT Catapult) have announced a strategic initiative worth around £18 million.
The company’s £17.9m investment program aims to strengthen the UK’s Advanced Therapeutic Medicines (ATMP) clinical trial environment and maintain the UK’s global position as the location of choice for advanced therapy research. said Innovate UK’s Executive Director of Healthy Living and Healthcare. Agriculture Dr. Stella Peace.
She said: “From initial investment to now overseeing the delivery of our new four-year programme, our aim is to ensure the UK maintains its global leadership in clinical research.
“Our commitment to fostering innovation and scientific progress is critical to maintaining this leadership. This not only accelerates medical advances, but also attracts investment and advances in advanced technology. It will strengthen the UK economy by creating much-needed jobs and being at the forefront of innovative medical discoveries.”
The scheme will provide an additional four years of funding to the Advanced Care Treatment Center Network. The funding will come from the NIHR and Innovate UK will oversee spending.
The CGT Catapult will coordinate the ATTC network, which currently comprises three centres: Innovation Manchester Advanced Therapies Center Hub, Midlands Wales Advanced Therapies Treatment Center and Northern Alliance Advanced Therapies Treatment Center.
The UK is the world leader in ATMP clinical research, with an estimated 9% of the world’s ATMP clinical trials being carried out domestically, with a total of 175 clinical trials currently underway.
The partner organizations say more products are in development, with a focus on ensuring the NHS can scale up advanced treatments for patients.
photograph: Chokniti Hongchum
[ad_2]
Source link
